Serratus Anterior Plan Block and Postoperative Pain in Patients Who Underwent Minimally Invasive Cardiac Surgery

April 16, 2024 updated by: Yavuz Orak, Kahramanmaras Sutcu Imam University

Investigation of the Effect of Serratus Anterior Plan Block on Postoperative Pain in Patients Who Underwent Minimally Invasive Cardiac Surgery.

Acute postoperative pain is defined as sudden onset pain that develops after stimulation due to surgical intervention. It is most severe in the first 24 hours after surgery and gradually decreases in severity and creates dissatisfaction in the patient. Postoperative pain that cannot be treated properly can cause various systemic effects, prolongation of hospital stay, decrease in patients' quality of life, and development of chronic pain. An increase in blood pressure, heart rate, cardiac irritability and systemic vascular resistance is observed with the sympathetic response due to pain. Increased myocardial workload and oxygen consumption may increase or trigger myocardial ischemia. Pulmonary dysfunction has an important place in the determination of mortality and morbidity after surgery and anesthesia.Especially in patients who have undergone thoracic surgery, pain limits the movements of the thoracic muscles, reducing functional residual capacity and vital capacity.This causes the development of atelectasis in the patient and the development of hypoxia and pneumonia due to the deterioration of the ventilation/perfusion ratio. Effective analgesia can be achieved in the postoperative period by administering a certain volume of local anesthetic between any two muscle planes using USG. In SAPB, a local anesthetic is injected between the serratus anterior muscle and the latissimus dorsi muscle to create sensory paresthesia in the thoracic wall. It is known to reduce pain scores in the postoperative period.

Serratus anterior plane block is a safe facial plane block performed under USG guidance.Depending on the application site of the block and the amount of local anesthetic administered, different numbers of intercostal nerves, long thoracic nerves and thoracodorsal nerves may be affected. The fact that Serratus anterior plane block (SAPB) is effective between T2-T9 dermatomes enables it to be used effectively in lateral thoracic wall surgeries.

Study Overview

Status

Completed

Detailed Description

Patients between the ages of 18-65 who will undergo minimally invasive cardiac surgery under elective conditions will be included in the study.

Patients will be randomized. The patients will be included in the study after they are informed about the study and their consent is obtained with the patient consent form. Patient groups will be divided into two groups as SAPB Group (n=20) and Control Group (n=20). All patients will be intubated with a double lumen endotracheal intubation tube in accordance with general anesthesia rules. Patients' age, weight, height, body mass index (BMI), additional disease, surgery, medications used, Ejection/Fraction, platelet count (x10/L), cardiopulmonary bypass time (min), aortic cross clamp time (min) , intraoperative remifentanil amount (mcq), intraoperative morphine dose (0.1 mg/kg), postoperative extubation time (min), post extubation, 1. hour, 2nd hour, 4th hour, 8th hour, 12th hour, 24th hour NRS (Numerical Rating Scale) pain score (between 0 and 10, no pain at 0, maximum pain at 10), extubation after, 1st hour, 2nd hour, 4th hour, 8th hour, 12th hour, 24th hour morphine consumption (Patient Controlled Analgesia), how many additional doses paracetamol was administered, how many additional doses were administered, additional analgesic need time (minutes), postoperative hemodynamic monitoring, 1st hour, 2nd hour, 4th hour, 8th hour, 12th hour, 24th hour PH, PO2 (oxygen pressure) ), MAP (mean arterial pressure), will be recorded. In addition, nausea, vomiting, itching, constipation, and the duration of intensive care hospitalization will also be recorded in the postoperative period. The patient will be told to express the degree of postoperative pain using the numerical scoring scale (NRS) before the operation. The patient will be informed about the PCA to be inserted in the postoperative period. After the surgical procedure is completed, serratus anterior plane block will be applied to the patients under the guidance of postoperative USG. After the surgery, the patients will be transferred to the cardiovascular surgery intensive care unit.

Serratus Anterior Plan (SAP) Block:

After the operation is completed, the block operation will be performed while intubated. The patient will be in the supine position.

The area where the procedure will be performed will be cleaned with povidone iodine. With a high frequency (10-18 MHz) ultrasound linear probe covered with a sterile sheath, using the 'in plane' technique using a 22-gauge, 80 mm insulated Quincke type needle, midaxillary line with the latissimus dorsi muscle and serratus at the level of the 4th and 5th ribs. After determining the fascia between the two muscles by imaging the muscle, the block needle will be advanced from caudal to cranial and 40 ml of 0.25% bupivacaine will be injected on the serratus muscle between the two muscles. No block will be applied to the control group. Only the PCA (Patient Control Analgesia) drug with Morphine will be used.

In the intensive care unit, the patients will be extubated after respiratory effort appears, when the patient is awake, blood gas values are within the normal range, body temperature is normal, and hemodynamically stable. When NRS is >3-4, patients will be instructed to press the PCA device. If the patient's consciousness and hemodynamic status do not allow for pain assessment, the patient will be excluded from the study.

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Kahramanmaraş, Turkey, 46040
        • Kahramanmaraş Sütçü İmam University Faculty of Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Between the ages of 18-65,
  • Coronary artery patients with normal left ventricular function and scheduled for elective coronary artery bypass surgery,
  • Valve diseases for which elective valve replacement is planned with normal left ventricular function,
  • Cases of ASD (Atrial Septal Defect) for atrial septal defect closure
  • Patients who will have elective valve + coronary artery bypass without left ventricular dysfunction and patients who volunteer to participate in the study,
  • No coagulation disorder
  • Patients with a platelet count of more than 100,000,
  • Patients with good mental status,
  • Patients with an ejection difference value (E/F) above 50% will be included in the study.

Exclusion Criteria:

  • Cases that will require emergency and repeat heart surgery,
  • With advanced left coronary artery disease and left ventricular dysfunction,
  • Receiving preoperative inotropic support therapy for any reason,
  • Mitral stenosis with atrial thrombus,
  • Patients with low cardiac out put syndrome and E/F below 50%,
  • Patients who need intra-aortic balloon pump during surgery,
  • Patients with bleeding and coagulation disorders,
  • Patients with hepatic and renal dysfunction,
  • Patients with Uncontrolled Diabetes Mellitus and Chronic Obstructive Pulmonary Disease,
  • Patients allergic to opioids, analgesics and bupivacaine,
  • Patients with atrial fibrillation using anticoagulants,
  • Patients with cognitive dysfunction
  • Patients who do not want to participate in the study will be excluded from the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Group SAPB (Serratus anterior plane block)

Active Comparator: Group SAPB (Serratus anterior plane block) After the operation is completed, the block operation will be performed while intubated. The patient will be in the supine position.

The area where the procedure will be performed will be cleaned with povidone iodine.

The latissimus dorsi muscle and the serratus muscle will be visualized at the level of the 4th and 5th ribs using a 22-gauge, 80 mm insulated Quincke type needle with the 'in plane' technique, accompanied by a high frequency (10-18 MHz) ultrasound linear probe covered with a sterile sheath. .

After the fascia between the two muscles is fixed, the block needle will be advanced from caudal to cranial and 40 ml (20 ml local anesthetic + 20 ml saline) 0.25% local anesthetic will be injected on the serratus muscle between the two muscles.

The patient will be in the supine position. The area where the procedure will be performed will be cleaned with povidone iodine. Using a 22-gauge, 80 mm insulated Quincke needle with a high frequency (10-18 MHz) ultrasound linear probe covered with a sterile sheath, the latissimus dorsi muscle and the serratus muscle will be visualized at the level of the 4th and 5th ribs. After determining the fascia between the two muscles, the block needle will be advanced from caudal to cranial and 40 ml of 0.25% bupivacaine (local anesthetic) will be injected on the serratus muscle between the two muscles.
No Intervention: Group Control
The action will not be applied

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Morphine consumption by PCA (Patient Control Analgesia)
Time Frame: The change from baseline in the postoperative period at the 1, 2, 4, 8, 12 and 24th hour after extubation
Morphine consumption used in case of pain
The change from baseline in the postoperative period at the 1, 2, 4, 8, 12 and 24th hour after extubation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
pain (NRS)score
Time Frame: Change from baseline of NRS Score at 1,2, 4,,8, 12 and 24 hours after being extubated will be recorded.
Change from baseline NRS Score. from 1 to 10 , 0: No pain, 10: 10 pain that can not be
Change from baseline of NRS Score at 1,2, 4,,8, 12 and 24 hours after being extubated will be recorded.
PH
Time Frame: Change from baseline of PH at the 1, 2, 4, 8, 12 and 24th hour after extubation
PH change after extubation
Change from baseline of PH at the 1, 2, 4, 8, 12 and 24th hour after extubation
PO2
Time Frame: Change from baseline of PO2 at the 1, 2,4 , 8, 12 and 24th hour after extubation
PO2 change after extubation
Change from baseline of PO2 at the 1, 2,4 , 8, 12 and 24th hour after extubation
Mean Arterial Pressure (MAP)
Time Frame: Change from baseline of MAP at the 1, 2, 4, 8, 12 and 24th hour after extubation
MAP change after extubation
Change from baseline of MAP at the 1, 2, 4, 8, 12 and 24th hour after extubation
PCO2
Time Frame: Change from baseline of PCO2 change at the 1, 2, 4, 8, 12 and 24th hour after extubation
PCO2 change after extubation
Change from baseline of PCO2 change at the 1, 2, 4, 8, 12 and 24th hour after extubation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Yavuz Orak, Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi, Anesteziyoloji ve Reanimasyon Bölümü

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2023

Primary Completion (Actual)

February 15, 2024

Study Completion (Actual)

April 10, 2024

Study Registration Dates

First Submitted

May 31, 2023

First Submitted That Met QC Criteria

August 18, 2023

First Posted (Actual)

August 21, 2023

Study Record Updates

Last Update Posted (Actual)

April 17, 2024

Last Update Submitted That Met QC Criteria

April 16, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pain

Clinical Trials on SAPB (Serratus Anterior Plan) Block

Subscribe